Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of PF-07265803 in LMNA-related dilated cardiomyopathy
MOH_2022-04-10_010693Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of emprumapimod in dilated cardiomyopathy (DCM), cardiolaminopathy (LMNA-DCM) and heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by Pfizer. Primary endpoint: Change in 6-minute walk distance. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
emprumapimod
03
Conditions
dilated cardiomyopathy (DCM)cardiolaminopathy (LMNA-DCM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on MOH_2022-04-10_010693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-10_010693.